We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

Geistlich TauroSept®

Safety in use due to outstanding systemic tolerability

Taurolidine is also licensed as an active pharmaceutical ingredient for the local treatment of infections such as peritonitis; up to 200 ml of taurolidine 2 % are instilled daily into the abdominal cavity and absorbed fully through the peritoneum. So far, no systemic side effects have been identified. The safety of taurolidine has also been confirmed in clinical studies with long-term intravenous administration of high doses (up to 20 g daily). (1) In the body, taurolidine is metabolised rapidly via the metabolites taurultam and methylol taurinamide, which also have an anti-microbial action, to taurine, an endogenous aminosulphonic acid, CO₂ and H₂O. (2) Therefore, no toxic effects are known or expected in the event of accidental injection.

 

References:

  1. Gong, L., H. E. Greenberg, et al. (2007). “The pharmacokinetics of taurolidine metabolites in healthy volunteers.” J Clin Pharmacol 47(6): 697–703.
  2. Knight, B. I., G. G. Skellern, et al. (1981). “The characterisation and quantitation by high- performance liquid chromatography of the metabolites of taurolin.” Br J Clin Pharmacol 12 (3): 439–40.